Table 1 Baseline characteristics of the patients included in the study
From: Causes of death after first time venous thromboembolism
Variables | All patients | Control | DVT | PE |
|---|---|---|---|---|
Number of patients, n (%) | 359,884 (100) | 352,288 (97.9) | 4,384 (1.2) | 3,212 (0.9) |
Age, years (mean, SD) | 48.5 (12.2) | 48.4 (12.1) | 53 (13.3) | 55.2 (13.8) |
Age 18–49 | 174,878 (48.6) | 173,365 (49.2) | 1,033 (23.6) | 480 (17.6) |
Age 50–79 | 144,238 (40.1) | 139,663(39.6) | 2,564(58.5) | 2,011 (62.6) |
Age 80+ | 40,786 (11.3) | 39,260 (11.1) | 787 (18.0) | 721 (22.4) |
Male sex, n (%) | 157,102 (43.7) | 153, 321(43.5) | 2,182 (49.8) | 1,599(49.8) |
Cardiovascular disease | 15,053(4.2) | 14,556(4.1) | 228(5.2) | 269(8.4) |
Atrial_fibrillation | 18,654 (5.2) | 18,181 (5.2) | 256 (5.8) | 217 (6.8) |
COPD | 8,023 (2.2) | 7,583 (2.2) | 175(4.0) | 265 (8.3) |
Diabetes | 20,912(5.8) | 20,258 (5.8) | 333(7.6) | 321 (10.0) |
HF | 10,916 (3.0) | 10,471(3.0) | 190(4.3) | 255(7.9) |
Hypertension | 43,977(12.2) | 42,158(12.0) | 144 (3.0) | 175 (5.6) |
Obesity | 7564 (2.1) | 1,572 (0.4) | 15 (0.3) | 10 (0.3) |
Renal_disease | 7115 (2.0) | 6762 (1.9) | 199 (4.5) | 154(4.8) |
Peripheral_Vascular_disease | 3093(0.9) | 2969 (0.8) | 64 (0.4) | 60 (0.3) |
Liver disease | 2416 (0.7) | 2308 (0.7) | 76 (1.7) | 32(1.0) |
Cancer | 26,021(7.9) | 24,371(6.9) | 797(18.2) | 853(26.6) |
Stroke/ischemic | 9890 (2.7) | 9456 (2.7) | 48 (1.0) | 26 (0.82) |
Anithypertensives | 107,015(29.7) | 103,544(29.4) | 1811(41.3) | 1660(51.7) |
Insulin | 12,133(3.4) | 11,804(3.4) | 165(3.8) | 164(5.1) |
Oral diabetes agent | 17,269(4.8) | 16,863(4.8) | 207(4.7) | 199(6.2) |
Lipid_lowering | 46,600 (12.9) | 45,310(12.9) | 683(15.6) | 607(18.9) |
Aspirin | 35,168(9.8) | 34,086(9.7) | 555 (12.7) | 527(16.4) |
LMWH | 17,547(4.9) | 13,356(3.8) | 2728(62.2) | 1463(45.5) |
DOAC | 12,609(3.5) | 9,293(2.6) | 1744(39.8) | 1572(48.9) |
Warfarin | 7,728(2.1) | 7,202(2.0) | 210(4.8) | 316(9.8) |